UBS lowered the firm’s price target on Colgate-Palmolive (CL) to $98 from $100 and keeps a Buy rating on the shares. The firm thinks Q1 results for much of the consumer staples group will be “okay” as organic revenue growth will show signs of improvement and stabilization, though the issue centers on how companies will handle forward looking commentary as inflation is likely to pose a greater risk to earnings in the second half and potentially beyond, the analyst tells investors in a preview for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- TD downgrades Colgate-Palmolive on higher oil-based input costs
- Colgate-Palmolive downgraded to Hold from Buy at TD Cowen
- Colgate-Palmolive upgraded to Buy from Hold at Deutsche Bank
- Colgate-Palmolive Announces Global Segment Realignment for 2026
- FedEx (FDX) Q3 Earnings This Week — Why Oil Prices Could Be the Key Driver
